Umfrage zur Nutzung unserer Internetseite
Sehr geehrte/r Besucher/in unseres Internetauftrittes,

wir, das Universitätsklinikum Halle (Saale), führen im Moment eine Umfrage über die Nutzung unserer Internetseite durch. Mit den Ergebnissen dieser völlig anonymen und freiwilligen Umfrage wollen wir unsere Seite für Sie attraktiver und besser nutzbar machen. Wir würden uns deshalb sehr über Ihre Teilnahme freuen. Das Beantworten der Fragen dauert auch nur wenige Minuten.

Unsere Datenschutzinformationen finden Sie unter Datenschutzerklärung
Ich möchte nicht teilnehmen

Dear collegues,

On behalf of the organizing committee we would like to invite you to join the 10th International Meeting “Tumor immunology meets oncology (TIMO X)”, which will be held in Halle/Saale, Germany, from May 22nd to 24th, 2014. 

During the last years tumor immunology has rekindled interest, since the molecular mechanisms and cellular processes involved in immune escape and immune suppression of tumors, which negatively interfere with antitumor immune responses have been well characterized. This leads to the development of novel immunotherapeutic approaches, which either enhance the stimulatory activity of immune cells and/or induce immunogenicity of tumor cells or repress the negative signals inhibiting immune responses. 

Interestingly, some of these novel immunotherapeutics, e.g. antibodies directed against anti-CTLA4 and the PD-1/PDL-1, demonstrated a high efficacy in tumor patients and have been recently approved by the FDA or are currently employed/derived in clinical phase I to phase III trials. In addition, different targeted therapies mainly affecting receptor tyrosine kinases and different signal transduction pathways also demonstrated an increased survival of tumor patients, although patients often develop resistances to these substances. Some of these tyrosine kinase inhibitors have been shown to modulate immune responses by decreasing the frequency of immune suppressive cells, like regulatory T cells and myeloid-derived suppressor cells or by impairing the function of CD4+ and CD8+ T cells. Recently, therapies combining immunotherapies with targeted drugs have been shown to increase immune responses and enhance the outcome of tumor patients. However, the mode of combination and treatment sequence have not yet been established and still need further optimization. Based on the novel knowledge in tumor immunology and targeted therapies the meeting will focus on different immune escape strategies of tumors, the role of the tumor microenvironment and innate and adaptive immune cells in tumor immune surveillance and in modulating immune response, the identification of biomarkers for monitoring the efficacy of immunotherapies as well as results from clinical trials using different immune therapeutic strategies alone or in combination with targeted therapies. 

We are sure that your participation will contribute to make this meeting exciting and successful. You are cordially invited to join this symposium in the beautiful town of Halle on the river Saale.


Yours sincerely,


On behalf of the organizer team,

Prof. Dr. Barbara Seliger


Organizer:                   Barbara Seliger, Halle/Saale


Scientific Committee:   Michael Bachmann (Dresden)

                                    Elfriede Nössner (Munich)

                                    Rudolf Lichtenfels (Halle/Saale)


Congress Secretary:    Sylvi Magdeburg

                                     Institute for Medical Immunology 

                                     Magdeburger Str. 2

                                     D-06112 Halle/Saale

                                     Phone: +49-345-557 5041 or 4054

                                     Fax: +49-345-557 4055


Location:                       Lecture hall 4 building 5 

                                      University Hospital Halle-Kroellwitz

                                      Ernst-Grube-Str. 40

                                      D-06120 Halle/Saale

        Directions University Hospital Maps